Key result
Astaxanthin enhances radiation cytotoxicity in breast cancer cells, reducing IC50 ~10-fold.
Why the study?
Radiotherapy efficacy is limited by severe side effects, and astaxanthin requires further investigation for its role and pro-oxidant potential in cancer therapy radiosensitization.
Does astaxanthin enhance the cytotoxic effects of ionizing radiation in MCF7 breast cancer cells?
Does astaxanthin enhance the cytotoxic effects of ionizing radiation in MCF7 breast cancer cells?
Astaxanthin acts as a radiosensitizer in MCF7 breast cancer cells by inducing apoptosis, disrupting the cell cycle, and exhibiting anti-metastatic activity.
Answers are grounded in this paper and cite their sources.
Hypothesis-generating for astaxanthin radiosensitization in breast cancer cells; prospective trials needed before clinical consideration.
Background Radiotherapy (RT) is a primary treatment for cancer, including breast cancer, but its effectiveness is limited by severe side effects. Radiosensitization using natural products can enhance efficacy while reducing radiation doses. Astaxanthin (AST), a natural carotenoid with antioxidant properties, requires further investigation for its role in cancer therapy. Especially in many previous studies, AST found to has prooxidant effect in cancer cells reverse its antioxidant effect in normal cells. Methods This study explored AST’s potential to enhance the cytotoxic effects of ionizing radiation (IRR) against MCF7 breast cancer cells and the underlying mechanisms. Cytotoxicity, apoptosis induction, anti-metastatic activity, and cell cycle distribution were analyzed in response to IRR with and without AST. Results IRR alone showed limited cytotoxicity, whereas addition of AST significantly enhanced IRR’s effects, reducing IC 50 by ten folds in combination treatment. AST increased apoptosis markers (caspase-3 and BAX/BCL2 ratio) by 16% and 67.8%, respectively. It also decreased proliferation index and S-phase ratio by 43.24% and 42.6%, respectively. AST further reduced metastatic markers MMP2 and MMP9 by 25% and 33.8%, respectively, in combination therapy. Additionally, AST exhibited a pro-oxidant effect, elevating MDA and H₂O₂ levels by 16.9% and 18.9%, respectively. It also caused cell cycle arrest at the S and G2/M phases, making cells more susceptible to IRR. Conclusion These findings confirm AST’s radiosensitizing effect via apoptosis induction, cell cycle disruption, and anti-metastatic activity, supporting its potential in enhancing radiotherapy efficacy for breast cancer cells. Further research is warranted to explore its application in cancer treatment.
No takes yet. Share an insight, caveat, or question.
Awady et al. (2026) studied Breast cancer (MCF7 cell line). Astaxanthin and Ionizing Radiation vs. Ionizing radiation alone was evaluated on Cytotoxicity (IC50) (10-fold reduction in IC50, p=<0.05). The addition of astaxanthin significantly enhanced the cytotoxic effects of ionizing radiation on MCF7 breast cancer cells, reducing the IC50 by ten-fold in combination treatment.
Synapse has enriched 10 related papers. Consider them for comparative context: